公开(公告)号：US06441148B1

公开(公告)日：2002-08-27

申请号：US09130337

申请日：1998-08-06

Applicant: Christopher C. A. Radomski ,  Kah Tong Seow ,  R. Antony J. Warren ,  Wai Ho Yap

Inventor： Christopher C. A. Radomski ,  Kah Tong Seow ,  R. Antony J. Warren ,  Wai Ho Yap

IPC: C07H2102

CPC classification number: C12Q1/6876 ,  C12N9/248 ,  C12N15/10 ,  C12Q1/6806 ,  C12Q1/686 ,  C12Y302/01008 ,  C12Y302/01032

Abstract: Xylanase DNA is recovered from soil by PCR amplification using degenerate primers. Because of the complexity of the soil samples, it is likely that the recovered product will include more than one species of polynucleotide. These recovered copies may be cloned into a host organism to produce additional copies of each individual species prior to characterization by sequencing. Recovered DNA which is found to vary from known xylanases can be used in several ways to facilitate production of novel xylanases for industrial application. First, the recovered DNA, or probes corresponding to portions thereof, can be used as a probe to screen DNA libraries and recover intact xylanase genes including the unique regions of the recovered DNA. Second, the recovered DNA or polynucleotides corresponding to portions thereof, can be inserted into a known xylanase gene to produce a recombinant xylanase gene with the sequence variations of the recovered DNA.

Abstract translation: 通过使用简并引物的PCR扩增从土壤中回收木聚糖酶DNA。 由于土壤样品的复杂性，回收的产品很可能包含多于一种的多核苷酸。 在通过测序表征之前，将这些回收的拷贝克隆到宿主生物体中以产生每个单独物种的额外拷贝。 发现与已知的木聚糖酶不同的回收的DNA可以以多种方式用于促进用于工业应用的新型木聚糖酶的生产。 首先，回收的DNA或对应于其部分的探针可用作探针以筛选DNA文库并回收完整的木聚糖酶基因，包括回收的DNA的独特区域。 其次，将回收的DNA或与其部分相当的多核苷酸插入已知的木聚糖酶基因中以产生具有回收DNA序列变异的重组木聚糖酶基因。

公开(公告)号：US06410261B1

公开(公告)日：2002-06-25

申请号：US08965272

申请日：1997-11-06

Applicant: Laurie H. Glimcher ,  Hong Zhou

Inventor： Laurie H. Glimcher ,  Hong Zhou

IPC: C07H2102

Abstract: Isolated nucleic acid molecules encoding a novel protein, CIP104, that interacts with CIITA, an MHC class II transcriptional activator, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a CIP104 transgene. The invention further provides isolated CIP104 proteins and peptides, CIP104 fusion proteins and anti-CIP104 antibodies. Methods of using the CIP104 compositions of the invention are also disclosed, including methods for detecting CIP104 activity (e.g., CIP104 protein or mRNA) in a biological sample, methods of modulating CIP104 activity in a cell, and methods for identifying agents that modulate an interaction between CIP104 and CIITA.

公开(公告)号：US06388062B1

公开(公告)日：2002-05-14

申请号：US09305914

申请日：1999-05-05

Applicant: Thanos D. Halazonetis ,  Elena S. Stavridi

Inventor： Thanos D. Halazonetis ,  Elena S. Stavridi

IPC: C07H2102

CPC classification number: C07K14/4746 ,  Y10S530/827

Abstract: Modified p53 tetramerization domains which do not hetero-oligomerize with native p53 tetramerization domains are described. These modified p53 tetramerization domains have one or more of the following substitutions in the region of residues 325 to 355 of human p53: Leu330 substituted with Phe; Met340 substituted with Phe; Ala347 substituted with Ile; Leu348 substituted with Met; Ala353 substituted with Leu; Gln354 substituted with Leu; Ala355 substituted with Asp. Also described are p53 proteins containing these modified p53 tetramerization domains linked to a p53 DNA binding domain. These proteins and the nucleic acid sequences encoding them, are useful in ameliorating conditions associated with inappropriate p53 function.

Abstract translation: 描述了不与天然p53四聚化结构域异齐聚的修饰的p53四聚体结构域。 这些修饰的p53四聚体结构域在人p53：被Phe取代的Leu330的残基325至355的区域中具有一个或多个以下取代基; 用Phe取代的Met340; 用Ile取代的Ala347; 用Met取代Leu348; 被Leu取代的Ala353; 被Leu取代的Gln354; 用Ala取代的Ala355。 还描述了含有与p53 DNA结合结构域连接的这些修饰的p53四聚化结构域的p53蛋白。 这些蛋白质和编码它们的核酸序列可用于改善与不适当p53功能相关的病症。

公开(公告)号：US06384206B1

公开(公告)日：2002-05-07

申请号：US09247137

申请日：1999-02-09

Applicant: Harlan D. Caldwell ,  Yuan Ying ,  You-Xun Zhang ,  Nancy G. Watkins

Inventor： Harlan D. Caldwell ,  Yuan Ying ,  You-Xun Zhang ,  Nancy G. Watkins

IPC: C07H2102

CPC classification number: C07K14/295 ,  A61K39/00

Abstract: The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.

Abstract translation: 披露沙眼衣原体15个血清型的主要外膜蛋白的四个可变结构域的核苷酸和推断的氨基酸序列以及这些结构域的序列和免疫原性分析。

公开(公告)号：US06369208B1

公开(公告)日：2002-04-09

申请号：US08973137

申请日：1998-03-30

Applicant: James L. Cole ,  Lawrence C. Kuo ,  David B. Olsen ,  Fritz Benseler

Inventor： James L. Cole ,  Lawrence C. Kuo ,  David B. Olsen ,  Fritz Benseler

IPC: C07H2102

CPC classification number: C12N15/115 ,  A61K38/00 ,  C07H21/00 ,  C12N15/1131 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3513 ,  C12N2310/3521

Abstract: A method is provided for making synthetic capped RNAs. These compounds serve as substrates for the virally encoded endonuclease associated with influenza virus. We are able to assay for this unique and specific viral activity of cleavage of a capped RNA in vitro. Therefore, screening of inhibitors of this activity is possible. In addition, short non-extendible (due to their length or because of the modification of the 3′-end of the oligo, i.e. 3′-dA) RNAs are potent inhibitors of the cleavage of capped RNAs by influenza endonuclease. Finally, these compounds may be used to investigate viral and cellular mechanisms of transcription/translation or mRNA maturation.

Abstract translation: 提供了制备合成上限RNA的方法。 这些化合物用作与流感病毒相关的病毒编码的内切核酸酶的底物。 我们能够测定这种在体外切割加盖RNA的独特且特异的病毒活性。 因此，可以筛选该活性的抑制剂。 此外，短的不可延伸的（由于其长度或由于寡核苷酸的3'末端的修饰，即3'-dA）RNA是流感内切核酸酶切割加帽RNA的有效抑制剂。 最后，这些化合物可用于研究转录/翻译或mRNA成熟的病毒和细胞机制。

公开(公告)号：US06359124B1

公开(公告)日：2002-03-19

申请号：US09248386

申请日：1999-02-12

Applicant: David J. Ecker ,  Phillip Dan Cook ,  Brett P. Monia ,  Susan M. Freier ,  Yogesh S. Sanghvi

Inventor： David J. Ecker ,  Phillip Dan Cook ,  Brett P. Monia ,  Susan M. Freier ,  Yogesh S. Sanghvi

IPC: C07H2102

CPC classification number: C12N15/1135 ,  C07H21/00 ,  C12N2310/315 ,  C12N2310/318 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/346 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12N2310/3525

Abstract: Compositions and methods are provided for the modulation of expression of the human ras gene in both the normal and activated forms. Oligonucleotides are provided that have methylene(methylimino) linkages alternating with phosphorothioate or phosphodiester linkages. Further oligonucleotides are provide that have a first region having a methylene(methylimino) linkage alternating with a phosphorothioate or phosphodiester linkage and a second region having phosphorothioate linkages. Such oligonucleotides can be used for diagnostics as well as for research purposes including methods for diagnosis, detection and treatment of conditions arising from the activation of the H-ras gene.

Abstract translation: 提供组合物和方法用于调节正常和活化形式的人ras基因的表达。 提供了具有与硫代磷酸酯或磷酸二酯键交替的亚甲基（甲基亚氨基）键的寡核苷酸。 提供另外的寡核苷酸，其具有与硫代磷酸酯或磷酸二酯键交替的亚甲基（甲基亚氨基）键的第一区域和具有硫代磷酸酯键的第二区域。 这样的寡核苷酸可用于诊断以及研究目的，包括用于诊断，检测和治疗由H-ras基因激活产生的病症的方法。

公开(公告)号：US06342593B1

公开(公告)日：2002-01-29

申请号：US09095443

申请日：1998-06-10

Applicant: Gregory D. Plowman ,  Elior Peles

Inventor： Gregory D. Plowman ,  Elior Peles

IPC: C07H2102

CPC classification number: C12N9/1205 ,  C07K14/705 ,  C07K2319/00 ,  C12N9/16

Abstract: The present invention relates to Alp polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for Alp related diseases or conditions characterized by an abnormal interaction between an Alp polypeptide and an Alp binding partner.

Abstract translation: 本发明涉及Alp多肽，编码此类多肽的核酸，含有此类核酸的细胞，组织和动物，对这些多肽的抗体，利用此类多肽的测定法，以及与上述所有相关的方法。 为Alp相关疾病或特征为Alp多肽和Alp结合配偶体之间异常相互作用的病症提供治疗，诊断和筛选方法。

公开(公告)号：US06326477B1

公开(公告)日：2001-12-04

申请号：US09029755

申请日：1998-03-02

Applicant: Marja Ilmén ,  Hans Söderlund ,  Merja Penttilä

Inventor： Marja Ilmén ,  Hans Söderlund ,  Merja Penttilä

IPC: C07H2102

CPC classification number: C12N1/14 ,  C07K14/37 ,  C12N15/80 ,  C12P21/02

Abstract: The present invention relates to recombinant-DNA-technology, and particularly to genes involved in the control of basic metabolic processes in fungi. The invention specifically provides a mutated form of the native glucose repressor gene cre of filamentous fungi, wherein the mutation is situated in the C-terminal domain, the N-terminal first zinc finger being intact and the C-terminal region including the second zinc finger being mutated so that the viability of a strain carrying said mutated gene is maintained and the glucose repression is relieved.

Abstract translation: 本发明涉及重组DNA技术，特别涉及参与控制真菌中基本代谢过程的基因。 本发明具体提供了突变形式的丝状真菌的天然葡萄糖阻遏物基因cre，其中突变位于C末端结构域，N末端第一锌指是完整的，C末端区包括第二锌指 突变，使得携带所述突变基因的菌株的存活力得以维持并且葡萄糖抑制得到缓解。

公开(公告)号：US06313277B1

公开(公告)日：2001-11-06

申请号：US09245808

申请日：1999-02-05

Applicant: Douglas D. Ross ,  L. Austin Doyle ,  Lynne V. Abruzzo

Inventor： Douglas D. Ross ,  L. Austin Doyle ,  Lynne V. Abruzzo

IPC: C07H2102

CPC classification number: G01N33/57415 ,  A61K31/4985 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4702 ,  G01N2800/44

Abstract: The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.

Abstract translation: 描述了抗乳腺癌抗性蛋白，以及编码所述蛋白质的cDNA。 已经发现该蛋白质赋予对癌症化学治疗药物的抗性。

公开(公告)号：US06312947B1

公开(公告)日：2001-11-06

申请号：US09234186

申请日：1999-01-20

Applicant: H. Robert Horvitz ,  Michael Hengartner

Inventor： H. Robert Horvitz ,  Michael Hengartner

IPC: C07H2102

CPC classification number: C12Q1/6876 ,  A61K38/00 ,  C07K14/43581 ,  C07K14/4747 ,  C12Q2600/156

Abstract: The present invention relates to genes, referred to herein as cell death-protective genes, which protect cells against programmed cell death by antagonizing the activities of genes which cause cell death. As described herein, a cell death-protective gene from the nematode Caenorhabditis elegans, called ced-9, has been identified, sequenced, and characterized. ced-9 is essential for C. elegans development and apparently functions by protecting cells which normally live during development from programmed cell death. Mutations which constitutively activate and inactivate the ced-9 gene are also described. ced-9 was shown to function by antagonizing the activities of the cell death genes, ced-3 and ced-4. As further described, the protein product of the human oncogene bcl-2 was found to have a similar sequence to the Ced-9 protein. Methods and agents for both increasing and decreasing the occurrence of cell death are described that are potentially useful for diagnosis, prevention and therapy of diseases and conditions involving cell death; for the treatment of viral, parasitic, and other types of infection; and for killing organisms that are detrimental or potentially detrimental to the environment or to humans, pets, livestock, or agriculture.

Abstract translation: 本发明涉及本文称为细胞死亡保护基因的基因，其通过拮抗引起细胞死亡的基因的活性来保护细胞免于程序性细胞死亡。 如本文所述，已鉴定，测序和表征来自线虫秀丽隐杆线虫的细胞死亡保护基因，称为ced-9。 ced-9对于秀丽隐杆线虫的发育至关重要，并且显然通过保护通常在程序性细胞死亡过程中生存的细胞起作用。 还描述了组成型激活和灭活ced-9基因的突变。 ced-9显示通过拮抗细胞死亡基因ced-3和ced-4的活性起作用。 如进一步所述，发现人癌基因bcl-2的蛋白质产物具有与Ced-9蛋白相似的序列。 描述了增加和减少细胞死亡发生的方法和试剂，其潜在地用于诊断，预防和治疗涉及细胞死亡的疾病和病症; 用于治疗病毒，寄生虫等感染类型; 并且用于杀死有害或可能对环境或人类，宠物，家畜或农业有害的生物。